CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2)


Cell-based therapy offers great promise for treating degenerative diseases. Although autologous cell-based therapy is ideal, it may be impractical due to the high manufacturing cost and long production time. Allogeneic cell-based therapy offers a more cost-effective alternative; however, the risk of graft rejection is a major concern. Here, we generated HLA class-I and -II null iPSC line by knocking out CIITA gene in the B2M-knockout MUSIi001-A-1 cell line using CRISPR/Cas9 system. The MUSIi001-A-2 line provides a valuable model for studying immunological responses against allogeneic T cells and serves as a prototype for developing specific cell types for future cell-based therapy. Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Authors Thongsin N, Suwanpitak S, Wattanapanitch M
Journal Stem cell research
Publication Date 2023 Sep;71:103138
PubMed 37343428
DOI 10.1016/j.scr.2023.103138

Research Projects

Cell Lines